Notably, their current hypothesis is that SEREX specifically identifies tumor/self antigens that are recognized by CD4+CD25+ regulatory T cells, and that without induction of an inflammatory immune response that includes CTL activity, immunization with SEREX-identified antigens alone may actually enhance tumor progression [40,41]. This evidence concerns the gene CD4 and neoplasm.